Table 2.
A1C ≥7.0% cohort |
A1C <7.0% cohort |
|||||
---|---|---|---|---|---|---|
Control | CGM | Difference ± SE | Control | CGM | Difference ± SE | |
QALWs | 21.68 ± 0.60 | 22.38 ± 1.08 | 0.70 ± 1.03 | 21.84 ± 0.66 | 23.23 ± 0.81 | 1.39 ± 0.69* |
Direct costs | $3,984 ± 242 | $6,375 ± 302 | $2,391 ± 376* | $3,412 ± 164 | $6,529 ± 277 | $3,117 ± 356* |
Indirect costs | $12,419 ± 3,478 | $15,979 ± 4,100 | $3,560 ± 5,781 | $17,352 ± 4,338 | $25,146 ± 6,238 | $7,794 ± 7,097 |
Total costs | $16,403 ± 3,493 | $22,354 ± 4,127 | $5,951 ± 5,847 | $20,764 ± 4,351 | $31,675 ± 6,292 | $10,991 ± 7,163 |
ICER [$/QALW (95% CI)] | $8,501 (not defined) | $7,849 (−3,397 [fourth quadrant, dominant] to 66,829 [first quadrant]) | ||||
ICER [$/QALY (95% CI)] | $442,052 (not defined) | $408,148 (−176,644 [fourth quadrant, dominant] to 3,475,108 [first quadrant]) |
Data are means ± SE, unless otherwise indicated. A1C ≥7.0% cohort is only for those aged ≥25 years. Indirect costs are estimated from reports of subject and parent hours devoted to diabetes care per day, number of days missed from work or school due to diabetes, and number of days of work underperformance. Dominant, intervention improves health at a lower cost compared with control. Not defined, there is so much uncertainty around the ICER that a 95% CI cannot be defined.
*P < 0.05.